<DOC>
	<DOCNO>NCT00469300</DOCNO>
	<brief_summary>Currently approve drug treatment herpes labialis ( cold sore ) exhibit low level efficacy due limited ability drug penetrate skin site herpes virus replicate . Iontophoresis use electric current enhance delivery drug skin . This trial test new iontophoretic device new acyclovir gel treat cold sore .</brief_summary>
	<brief_title>Iontophoretic Application Acyclovir Gel Treat Cold Sores</brief_title>
	<detailed_description>This multicenter , placebo control , randomize , double blind , subject initiate study safety efficacy single , 10-minute , topical iontophoretic application novel acyclovir 5 % gel episodic treatment recurrent herpes labialis . The design trial also allow comparison efficacy single iontophoretic treatment acyclovir gel within 1 hour first sign and/or symptom herpetic episode efficacy single iontophoretic treatment acyclovir gel 6 to18 hour first sign and/or symptom . Approximately 810 subject enrol treat 80 subject three treatment arm . Depending upon subject randomize trial , subject receive either : 1 ) iontophoretic treatment active gel within 1 hour first signs/and symptom , follow 6-18 hour later second treatment placebo gel ; 2 ) iontophoretic treatment placebo gel within 1 hour first signs/and symptom , follow 6-18 hour later second treatment active gel ; 3 ) iontophoretic treatment placebo gel within 1 hour first signs/and symptom , follow 6-18 hour later second treatment placebo gel . After enrol randomized study , subject sent home lock kit contain iontophoretic device either active placebo gel . At first sign and/or symptom recurrent herpetic episode ( prodromal erythema ) , lesion confirm telephone interview subject , upon confirmation lesion , subject give combination lock kit instructed begin treatment immediately . The subject instruct return clinic within 6 18 hour first sign and/or symptom second iontophoretic treatment , appropriate treatment arm randomize , evaluation . The subject visit clinic daily follow-up evaluation 3 14 day follow first treatment call 2 week last clinic visit final safety evaluation .</detailed_description>
	<mesh_term>Herpes Labialis</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>1 . Male female subject 1875 year age 2 . Female subject must use medically acceptable form birth control study . 3 . Subject must history recurrent herpes labialis report least 3 recurrence precede 12 month . 4 . Subject must provide voluntary write informed consent participate study . 1 . Subjects pacemaker , history cardiac arrhythmia conduction abnormality . 2 . Any evidence active malignancy immunodeficient disease within last 30 day . Subjects complete therapy consider unlikely relapse surgery evidence disease , eligible study . 3 . Subject require chronic use immunomodifying drug ( e.g . systemic steroid ) topical steroid near face ; use inhale steroid exclude subject study . 4 . Subject require chronic use antiviral medication . 5 . History allergic adverse response acyclovir , related antiviral drug , gel base . 6 . In female childbearing potential , positive urine pregnancy test time screen . 7 . Nursing mother . 8 . Subjects implantable electronic device . 9 . Subject body pierce around area ordinarily affect cold sore . 10 . Subject consider unreliable unable understand follow protocol direction unable comprehend satisfactorily assess herpetic lesion determine Investigator designee screening . 11 . Subject abnormal skin condition ( e.g . acne , eczema , psoriasis , albinism , chronic vesiculobullous disorder ) occur area ordinarily affect cold sore significant facial hair area cold sore might affect normal course cold sore might impair accurate evaluation cold sore lesion . 12 . Subject infection HSV1 isolate know resistant acyclovir , valacyclovir , famciclovir , ganciclovir . 13 . Subject herpes vaccine . 14 . Subject currently enrol another clinical trial involve use drug and/or device . 15 . Subject previously participate current study ( TPIH221 ) . 16 . Subject require chronic use analgesic , pain medication nonsteroidal antiinflammatory agent ( NSAIDs ) . 17 . Subject recent history renal dysfunction serious hepatic disease . 18 . Subject history alcoholism drug abuse within precede 12 month . 19 . Subject share household another subject already enrol study ( TPIH221 ) . If household member already complete study , currently enrol subject exclude . 20 . Subject institutionalize . 21 . Any history , Investigator 's judgment , make subject ineligible place subject undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>herpes labialis</keyword>
	<keyword>cold sore</keyword>
	<keyword>acyclovir</keyword>
	<keyword>iontophoresis</keyword>
	<keyword>topical</keyword>
</DOC>